This drug takes the first new approach to schizophrenia treatment in decades," Farchione continued. "This approval offers a ...
Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...
Doctors sometimes use lithium to treat schizophrenia. However, it is not a primary treatment method and evidence of its ...
Such is the case with newly approved Bristol-Myers Squibb drug Cobenfy. The underlying drug was first studied in Alzheimer’s ...
On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...
Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers ...
People with schizophrenia will have a new treatment option for the first time in more than three decades, after the Food and Drug Administration Thursday approved a new kind of drug. Studies ...
For the first time in nearly 30 years, the U.S. Food and Drug Administration has approved a new drug treating schizophrenia, ...
The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia,  the FDA announced Thursday.
The U.S. Food and Drug Administration approved a new schizophrenia treatment on Thursday for the first time in decades, ...
on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb, combines two drugs, xanomeline and trospium ...